May 7, 2024Open Access

Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials

Key Points

Key points are not available for this paper at this time.

Abstract

Multiple cardiovascular outcomes trials (CVOTs) have shown the efficacy of GLP-1RAs in reducing major adverse cardiovascular events (MACEs) for high-risk patients. However, some CVOTs failed to demonstrate cardiovascular benefits.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Rivera et al. (Tue,) studied this question.

synapsesocial.com/papers/68e6b28ab6db6435876338c4 https://doi.org/https://doi.org/10.1016/j.ajpc.2024.100679

Demander à l'IA

Bookmark

View Full Paper